The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2025 | RCAT Red Cat Holdings, Inc. | Nicholas Reyland Liuzza JR director | XIn-the-money exercise Common Stock | +100,000 | $1.50 | $150k | 487,445 | Jul 9, 2025 |
| May 20, 2025 | RCAT Red Cat Holdings, Inc. | Nicholas Reyland Liuzza JR director | XIn-the-money exercise Warrant (right to buy)derivative | -100,000 | $0.00 | $0 | 100,000 | Jul 9, 2025 |
| Jun 9, 2025 | RCAT Red Cat Holdings, Inc. | Nicholas Reyland Liuzza JR director | XIn-the-money exercise Warrant (right to buy)derivative | -100,000 | $0.00 | $0 | 0 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | George F Allen director | XIn-the-money exercise Time-Based LTIP Unitsderivative | -4,645 | $0.00 | $0 | 12,919 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | George F Allen director | XIn-the-money exercise Common Unitsderivative | +4,645 | $0.00 | $0 | 4,645 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | James C. Cherry director | XIn-the-money exercise Time-Based LTIP Unitsderivative | -4,645 | $0.00 | $0 | 12,919 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | James C. Cherry director | XIn-the-money exercise Common Unitsderivative | +4,645 | $0.00 | $0 | 4,645 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | Daniel A Hoffler director | XIn-the-money exercise Time-Based LTIP Unitsderivative | -11,824 | $0.00 | $0 | 12,919 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | Daniel A Hoffler director | XIn-the-money exercise Common Unitsderivative | +11,824 | $0.00 | $0 | 4,988,263 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | James A Carroll director | XIn-the-money exercise Time-Based LTIP Unitsderivative | -4,645 | $0.00 | $0 | 12,919 | Jul 9, 2025 |
| Jul 3, 2025 | AHRT Armada Hoffler Properties, Inc. | James A Carroll director | XIn-the-money exercise Common Unitsderivative | +4,645 | $0.00 | $0 | 4,645 | Jul 9, 2025 |
| Jun 27, 2025 | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +1,397,684 | $3.50 | $4.9M | 8,341,338 | Jul 1, 2025 |
| Jun 27, 2025 | CRVS Corvus Pharmaceuticals, Inc. | Orbimed Advisors LLC director, owner | XIn-the-money exercise Common Warrants (right to buy)derivativeindirect: See Footnotes | -1,397,684 | $0.00 | $0 | 0 | Jul 1, 2025 |
| Jun 27, 2025 | CRVS Corvus Pharmaceuticals, Inc. | Peter A. Thompson director, owner | XIn-the-money exercise Common Stockindirect: See Footnotes | +1,397,684 | $3.50 | $4.9M | 8,341,338 | Jul 1, 2025 |
| Jun 27, 2025 | CRVS Corvus Pharmaceuticals, Inc. | Peter A. Thompson director, owner | XIn-the-money exercise Common Warrants (right to buy)derivativeindirect: See Footnotes | -1,397,684 | $0.00 | $0 | 0 | Jul 1, 2025 |
| Jun 26, 2025 | ZYME Zymeworks Inc. | EcoR1 Capital, LLC director, owner | XIn-the-money exercise Common Stockindirect: See Note | +5,086,480 | $0.00 | $509 | 22,970,388 | Jun 27, 2025 |
| Jun 26, 2025 | ZYME Zymeworks Inc. | EcoR1 Capital, LLC director, owner | XIn-the-money exercise Pre-Funded Warrants (right to acquire)derivativeindirect: See note | -5,086,521 | $0.00 | $0 | 0 | Jun 27, 2025 |
| Jun 3, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Common Stock | +10,000 | $0.71 | $7,100 | 10,400 | Jun 24, 2025 |
| Jun 4, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Common Stock | +15,000 | $0.71 | $11k | 15,400 | Jun 24, 2025 |
| Jun 6, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Common Stock | +25,000 | $1.10 | $28k | 25,400 | Jun 24, 2025 |
| Jun 23, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Common Stock | +10,000 | $1.10 | $11k | 10,400 | Jun 24, 2025 |
| Jun 3, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Stock Options (Right to Buy)derivative | -10,000 | $0.71 | $7,100 | 40,000 | Jun 24, 2025 |
| Jun 4, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Stock Options (Right to Buy)derivative | -15,000 | $0.71 | $11k | 25,000 | Jun 24, 2025 |
| Jun 6, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Stock Options (Right to Buy)derivative | -25,000 | $1.10 | $28k | 27,500 | Jun 24, 2025 |
| Jun 23, 2025 | TGEN TECOGEN INC. | Stephen Lafaille VP of Business Development | XIn-the-money exercise Stock Options (Right to Buy)derivative | -10,000 | $1.10 | $11k | 17,500 | Jun 24, 2025 |
| Jun 20, 2025 | AEYE AUDIOEYE INC | James B Hawkins director | XIn-the-money exercise Common Stock | +1,000 | $16.00 | $16k | 129,916 | Jun 24, 2025 |
| Jun 20, 2025 | AEYE AUDIOEYE INC | James B Hawkins director | XIn-the-money exercise Common Stock | +7,600 | $15.00 | $114k | 137,516 | Jun 24, 2025 |
| Jun 20, 2025 | AEYE AUDIOEYE INC | James B Hawkins director | XIn-the-money exercise Put Option (obligation to buy)derivative | -10 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | AEYE AUDIOEYE INC | James B Hawkins director | XIn-the-money exercise Put Option (obligation to buy)derivative | -76 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | OTRK Ontrak, Inc. | Terren S Peizer CEO and Chairman of the Board | XIn-the-money exercise Common Stockindirect: By Humanitario | +500,000 | $0.00 | $700 | 2,305,480 | Jun 24, 2025 |
| Jun 20, 2025 | OTRK Ontrak, Inc. | Terren S Peizer CEO and Chairman of the Board | XIn-the-money exercise Pre-Funded Common Stock Purchase Warrantderivativeindirect: By Humanitario | -500,000 | $0.00 | $0 | 799,575 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By ADAR1 Partners, LP | -100 | $60.00 | $6,000 | 4,392,637 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By ADAR1 Partners, LP | -1,400 | $70.00 | $98k | 4,391,237 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Common Stockindirect: By Spearhead Insurance Solutions IDF, LLC | -200 | $70.00 | $14k | 743,358 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By ADAR1 Partners, LP | -1 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By ADAR1 Partners, LP | -14 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | KROS Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC owner | XIn-the-money exercise Put Option (right to sell)derivativeindirect: By Spearhead Insurance Solutions IDF, LLC | -2 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | - BlackRock Direct Lending Corp. | Institution for Social Security Public owner | XIn-the-money exercise Common Stock, $0.001 par value | +2,084,925 | $9.58 | $20M | 29,076,852 | Jun 24, 2025 |
| Jun 20, 2025 | - BlackRock Direct Lending Corp. | Institution for Social Security Public owner | XIn-the-money exercise Obligation to Buyderivative | -2,084,925 | - | - | 0 | Jun 24, 2025 |
| Jun 17, 2025 | STLN Oncology Institute, Inc. | Richard A Barasch director | XIn-the-money exercise Common Stockindirect: By LLC | +679,224 | $1.20 | $814k | 3,234,765 | Jun 24, 2025 |
| Jun 17, 2025 | STLN Oncology Institute, Inc. | Richard A Barasch director | XIn-the-money exercise Common Warrantderivativeindirect: By LLC | -679,224 | $0.00 | $0 | 0 | Jun 24, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise Common Stockindirect: Held by Barnett Equity Holdings, LLC | +2,255,048 | - | - | 3,976,063 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise Common Stockindirect: Held by Sixth Street Specialty Lending, Inc. | +118,687 | - | - | 1,129,212 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise Common Stockindirect: Held by Barnett Equity Holdings, LLC | +1,711,113 | - | - | 5,687,176 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise Common Stockindirect: Held by Sixth Street Specialty Lending, Inc. | +90,059 | - | - | 1,219,271 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise 2018 Warrantsderivativeindirect: Held by Barnett Equity Holdings, LLC | -13,009,892 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise 2018 Warrantsderivativeindirect: Held by Sixth Street Specialty Lending, Inc. | -684,731 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise 2020 Warrantsderivativeindirect: Held by Barnett Equity Holdings, LLC | -10,829,823 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 20, 2025 | CAI Caris Life Sciences, Inc. | TSSP Sub-Fund HoldCo LLC other | XIn-the-money exercise 2020 Warrantsderivativeindirect: Held by Sixth Street Specialty Lending, Inc. | -569,991 | $0.00 | $0 | 0 | Jun 23, 2025 |
| Jun 16, 2025 | TGEN TECOGEN INC. | Robert Panora COO and President | XIn-the-money exercise Common Stock | +12,723 | $0.79 | $10k | 82,723 | Jun 20, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.